Pfizer has developed an interesting technical setup: the stock is currently holding above a gap around $23.50, and a breakout above $26.50 could pave the way toward the $27.69 resistance level. With a stop‑loss placed at $23.58, this trade presents a strong risk‑to‑reward ratio.
From a fundamental perspective, Pfizer deserves attention for its ~7% dividend yield—sitting near the top among S&P 500 healthcare peers—which provides income while investors hold for longer‑term upside.
Though the short‑term target is $27.69, I view Pfizer as a long‑term hold with potential upside beyond the near‑term target, especially given dividend compounding and healthcare industry tailwinds.
https://www.tradingview.com/x/fY0lnN6K/
From a fundamental perspective, Pfizer deserves attention for its ~7% dividend yield—sitting near the top among S&P 500 healthcare peers—which provides income while investors hold for longer‑term upside.
Though the short‑term target is $27.69, I view Pfizer as a long‑term hold with potential upside beyond the near‑term target, especially given dividend compounding and healthcare industry tailwinds.
https://www.tradingview.com/x/fY0lnN6K/
免責事項
この情報および投稿は、TradingViewが提供または推奨する金融、投資、トレード、その他のアドバイスや推奨を意図するものではなく、それらを構成するものでもありません。詳細は利用規約をご覧ください。
免責事項
この情報および投稿は、TradingViewが提供または推奨する金融、投資、トレード、その他のアドバイスや推奨を意図するものではなく、それらを構成するものでもありません。詳細は利用規約をご覧ください。